Trial ID or NCT#



recruiting iconRECRUITING


The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.

Official Title

A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Prithvi Mruthyunjaya, MD, MHS
Prithvi Mruthyunjaya, MD, MHS
Professor of Ophthalmology and, by courtesy, of Radiation Oncology

Contact us to find out if this trial is right for you.


Mariana Nunez
(650) 723-6995